Prospects & Overviews
Current status of drug screening and disease modelling in human pluripotent stem cells
Article first published online: 8 AUG 2012
Copyright © 2013 WILEY Periodicals, Inc.
Special Issue: Stem Cells
Volume 35, Issue 3, pages 281–298, March 2013
How to Cite
Rajamohan, D., Matsa, E., Kalra, S., Crutchley, J., Patel, A., George, V. and Denning, C. (2013), Current status of drug screening and disease modelling in human pluripotent stem cells. Bioessays, 35: 281–298. doi: 10.1002/bies.201200053
- Issue published online: 11 FEB 2013
- Article first published online: 8 AUG 2012
- British Heart Foundation, Medical Research Council, Biotechnology and Biological Sciences Research Council and Engineering and Physical Research Council
- drug safety assessment;
- human embryonic stem cells;
- human induced pluripotent stem cells
The emphasis in human pluripotent stem cell (hPSC) technologies has shifted from cell therapy to in vitro disease modelling and drug screening. This review examines why this shift has occurred, and how current technological limitations might be overcome to fully realise the potential of hPSCs. Details are provided for all disease-specific human induced pluripotent stem cell lines spanning a dozen dysfunctional organ systems. Phenotype and pharmacology have been examined in only 17 of 63 lines, primarily those that model neurological and cardiac conditions. Drug screening is most advanced in hPSC-cardiomyocytes. Responses for almost 60 agents include examples of how careful tests in hPSC-cardiomyocytes have improved on existing in vitro assays, and how these cells have been integrated into high throughput imaging and electrophysiology industrial platforms. Such successes will provide an incentive to overcome bottlenecks in hPSC technology such as improving cell maturity and industrial scalability whilst reducing cost.